Patients with Obesity Have Better Long-Term Outcomes after Hospitalization for COPD Exacerbation

Abstract

Obesity has been shown to have a paradoxical benefit in a number of conditions, but the long-term effects in obesity after chronic obstructive pulmonary disease (COPD) exacerbation is still unclear. In this study, the effects of obesity on short- and long-term outcomes after a COPD exacerbation were evaluated. This was a secondary analysis of the Rapid Empiric Treatment with Oseltamivir Study (RETOS): a prospective, randomized, unblinded clinical trial. Patients were included in the study if they were hospitalized for acute exacerbation of COPD. Obesity was noted as patients with BMI >30. Clinical outcomes of time to clinical stability, length of stay, and mortality were compared. A total of 301 patients were included in the study, 122 (41%) patients were obese. There was no significant difference in the length of stay and time to clinical stability between patients with and without obesity. Mortality for patients with and without obesity was 3% and 3% at 30 days, 7% and 18% at six months, and 8% and 28% at one year, respectively. After adjusting with multivariable regression analysis, patients with obesity had a significant reduction in odds of dying at one year (adjusted odds ratio (aOR): 0.18; 95% CI: 0.06–0.58; p = .004) and at six months (aOR: 0.28; 95% CI: 0.09–0.89; p = .031). Our study showed that obesity was associated with reduced mortality at one year and six months after a COPD exacerbation. Although patients with obesity had higher rates of comorbidities, they had reduced mortality at one year after multivariable regression analysis.

Keywords:

• Obesity
• obesity paradox
• chronic obstructive pulmonary disease
• exacerbation
• mortality

Acknowledgments

DAD had full access of the data and the accuracy of the data analysis. DAD and RC contributed to the data interpretation and writing of manuscript. JAR contributed to the study design and writing of the manuscript. CG and SF contributed to data analysis and writing of the manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).